Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00242996
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • filgrastim — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • sargramostim — BIOLOGICAL
  • carmustine — DRUG
  • cyclophosphamide — DRUG
  • etoposide — DRUG
  • adjuvant therapy — PROCEDURE
  • bone marrow ablation with stem cell support — PROCEDURE
  • peripheral blood stem cell transplantation — PROCEDURE

Study Details

RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving chemotherapy, such as carmustine, etoposide, and cyclophosphamide, before transplant stops the growth of cancer cells by stopping them from dividing or killing them. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. More rituximab is given after transplant to kill any remaining cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with cyclophosphamide and G-CSF followed by combination chemotherapy works in treating patients undergoing an autologous stem cell transplant followed by rituximab and GM-CSF for refractory diffuse large B-cell lymphoma.

Key Dates

Start date
Mar 31, 2004
Status verified
Sep 2017
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007

Study Design

Enrollment
44 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

2-year event free survival

Locations (1)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-

Find similar trials in Baltimore, MD

By research site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies